BCT.V - BriaCell Therapeutics Corp.

TSXV - TSXV Delayed Price. Currency in CAD

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 West 15th Street
West Vancouver, BC V7T 2X1

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. William V. Williams M.D.CEO, Pres & Director227.75kN/AN/A
Dr. Charles Louis Wiseman M.D., FACPFounder & Director83.56kN/AN/A
Mr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBACFO & Corp. Sec.56.07kN/A1973
Ms. Farrah DeanMang. of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) for use in patients with breast cancer. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients; and BriaDX, its companion diagnostic test. Its preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. has a clinical trial collaboration and supply agreement with Incyte Corporation for developing Bria-IMT with compounds for treating breast cancer. The company is headquartered in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.